Search 7,500+ licensed pharmacies to find the best value, closest location, and fastest turnaround for
.
Tranexamic acid inhibits the interaction between UV-induced keratinocytes and melanocytes by blocking the plasminogen/plasmin pathway, reducing prostaglandin production and decreasing melanin synthesis — targeting melasma at its cellular root without traditional tyrosinase inhibition.
Topical tranexamic acid at therapeutic concentrations (2–5%) is not available as an FDA-approved commercial product. Compounding allows precise concentrations and combination with brightening agents like niacinamide, kojic acid, or azelaic acid.
Compare up to 7,500 pharmacies across the USA.
Tranexamic acid has been used systemically to reduce surgical bleeding for decades. Its use as a topical skin brightening agent emerged from dermatology research showing it effectively reduces melasma and post-inflammatory hyperpigmentation through a mechanism distinct from traditional tyrosinase inhibitors like kojic acid or hydroquinone.
Unlike hydroquinone, which carries risks of ochronosis and rebound hyperpigmentation, tranexamic acid has an excellent safety profile and is increasingly preferred for chronic melasma. It is often combined with niacinamide, kojic acid, or azelaic acid for synergistic brightening.
Plasminogen/Plasmin Pathway Inhibition
UV radiation activates plasminogen in keratinocytes, which converts to plasmin and stimulates arachidonic acid release. This triggers prostaglandin production which activates melanocytes to increase melanin synthesis. Tranexamic acid blocks plasminogen activation, interrupting this UV-induced melanogenesis cascade.
Keratinocyte-Melanocyte Interaction
By reducing keratinocyte prostaglandin output, tranexamic acid decreases paracrine signaling that normally stimulates melanocyte tyrosinase activity and melanosome transfer — reducing melanin production and its distribution to surrounding skin cells.
Melasma, post-inflammatory hyperpigmentation (PIH), uneven skin tone, sun damage pigmentation, periorbital hyperpigmentation, chloasma (pregnancy mask), acne scar discoloration
Post-acne hyperpigmentation, post-inflammatory hyperpigmentation from any cause, periorbital darkening (dark circles), rosacea-associated redness reduction (off-label), skin brightening maintenance after laser or chemical peel treatment
Standard concentration: 2–5% tranexamic acid
Application: Apply to affected areas twice daily (AM and PM)
Onset: 4–8 weeks for noticeable improvement; full results at 3–6 months
Sun protection: SPF 30+ daily is mandatory throughout treatment
No titration required. Begin twice-daily application (AM and PM) from day one. Patients with sensitive skin may start with once-daily application for the first 2 weeks before advancing to twice daily. Consistent daily sunscreen use is non-negotiable for efficacy.
Topical Cream (2–5%) — most common form; stable in a moisturizing cream base for daily use
Serum/Gel — lighter texture preferred for oily skin or warm climates; faster absorption
Combination Formulas — commonly combined with niacinamide (4–5%), kojic acid (1–2%), azelaic acid (10–15%), or vitamin C in a single compounded preparation for comprehensive brightening protocols
Combination with Tretinoin — tranexamic acid + tretinoin in a single formula for accelerated cell turnover and melanin reduction
Generally very well tolerated. Occasional mild irritation or dryness at application site. Significantly better tolerability than hydroquinone. No meaningful systemic absorption at topical concentrations. Suitable for long-term use.
Submit a quote request to find the lowest price. Quotes delivered to your inbox.
Find Lowest Price.png){kind=spacer}
